Pay in 4 interest-free payments of $6.83 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
468 GroblerCMaphumuloSCGrobbelaarLMBredenkampJCLaubscherGJLourensPJet al
C5 inhibitor treatment complement inhibitor treatment Side effects (5%) in patients treated with EMPAVELI in the PEGASUS study vs eculizumab The following reactions were mild or moderate in severity: diarrhea, fatigue, fever, viral infections, and injection site reactions Serious adverse reactions were reported in 17% of patients treated with EMPAVELI The most common serious adverse reaction was infections (5%) Breakthrough hemolysis occurred in 10% of those taking EMPAVELI vs 23% of those taking eculizumab at Week 16 in the PEGASUS study
EZH2 mutation or overexpression is detected in solid tumors and leukemia, and correlated with cancer metastasis [140,141,142]
Huster, D., Reichenbach, A
US$ 29.20
US$ 22.36
US$ 28.59
US$ 25.00
